Antagonism of CD317 Restriction of Human Immunodeficiency Virus Type 1 (HIV-1) Particle Release and Depletion of CD317 Are Separable Activities of HIV-1 Vpu

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 Feb 12

PMID 20147395

Citations 55

Authors

Christine Goffinet

Stefanie Homann

Ina Ambiel

Nadine Tibroni

Daniel Rupp

Oliver T Keppler

Oliver T Fackler

Affiliations

Soon will be listed here.

Abstract

Vpu antagonizes human immunodeficiency virus type 1 (HIV-1) particle release inhibition by CD317/BST-2/Tetherin. Whether this Vpu activity strictly requires cellular depletion of the restriction factor is unclear. Here, we characterized CD317 variants with mutations in putative sorting or ubiquitination motifs. All mutants still potently impaired release of Vpu-defective HIV-1 and remained sensitive to Vpu-mediated release enhancement. Importantly, this virological antagonism correlated with surface downregulation of CD317 mutants by Vpu, while intracellular pools of these mutants, which were consistently depleted of the wild-type protein, were highly variable or even enhanced. Thus, Vpu can efficiently antagonize virion tethering in the absence of CD317 degradation.

Citing Articles

ATG5 selectively engages virus-tethered BST2/tetherin in an LC3C-associated pathway.

Judith D, Versapuech M, Bejjani F, Palaric M, Verlhac P, Kuster A Proc Natl Acad Sci U S A. 2023; 120(20):e2217451120.

PMID: 37155854 PMC: 10193943. DOI: 10.1073/pnas.2217451120.

Medicinal chemistry strategies toward host targeting antiviral agents.

Ji X, Li Z Med Res Rev. 2020; 40(5):1519-1557.

PMID: 32060956 PMC: 7228277. DOI: 10.1002/med.21664.

The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.

Sharma S, Jafari M, Bangar A, William K, Guatelli J, Lewinski M J Virol. 2019; 93(11).

PMID: 30867310 PMC: 6532089. DOI: 10.1128/JVI.02315-18.

Characterization of E3 ligases involved in lysosomal sorting of the HIV-1 restriction factor BST2.

Roy N, Pacini G, Berlioz-Torrent C, Janvier K J Cell Sci. 2017; 130(9):1596-1611.

PMID: 28320822 PMC: 5450231. DOI: 10.1242/jcs.195412.

Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn G J Virol. 2017; 91(6).

PMID: 28077643 PMC: 5331793. DOI: 10.1128/JVI.02177-16.

References

Van Damme N, Goff D, Katsura C, Jorgenson R, Mitchell R, Johnson M . The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008; 3(4):245-52. PMC: 2474773. DOI: 10.1016/j.chom.2008.03.001. View

Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A . HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem. 2009; 284(23):15927-41. PMC: 2708888. DOI: 10.1074/jbc.M109.005124. View

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana I . Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009; 5(5):e1000429. PMC: 2673686. DOI: 10.1371/journal.ppat.1000429. View

McNatt M, Zang T, Hatziioannou T, Bartlett M, Fofana I, Johnson W . Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 2009; 5(2):e1000300. PMC: 2633611. DOI: 10.1371/journal.ppat.1000300. View

Rong L, Zhang J, Lu J, Pan Q, Lorgeoux R, Aloysius C . The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol. 2009; 83(15):7536-46. PMC: 2708638. DOI: 10.1128/JVI.00620-09. View

Sakuma T, Sakurai A, Yasuda J . Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses. PLoS One. 2009; 4(9):e6934. PMC: 2735005. DOI: 10.1371/journal.pone.0006934. View

Kaletsky R, Francica J, Agrawal-Gamse C, Bates P . Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A. 2009; 106(8):2886-91. PMC: 2650360. DOI: 10.1073/pnas.0811014106. View

Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V . HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009; 5(9):e1000574. PMC: 2729927. DOI: 10.1371/journal.ppat.1000574. View

Goila-Gaur R, Strebel K . HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 2008; 5:51. PMC: 2443170. DOI: 10.1186/1742-4690-5-51. View

10.

Dube M, Roy B, Guiot-Guillain P, Mercier J, Binette J, Leung G . Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol. 2009; 83(9):4574-90. PMC: 2668474. DOI: 10.1128/JVI.01800-08. View

11.

Neil S, Zang T, Bieniasz P . Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177):425-30. DOI: 10.1038/nature06553. View

12.

Bartee E, McCormack A, Fruh K . Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2007; 2(10):e107. PMC: 1626102. DOI: 10.1371/journal.ppat.0020107. View

13.

Goffinet C, Allespach I, Homann S, Tervo H, Habermann A, Rupp D . HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe. 2009; 5(3):285-97. DOI: 10.1016/j.chom.2009.01.009. View

14.

Perez-Caballero D, Zang T, Ebrahimi A, McNatt M, Gregory D, Johnson M . Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009; 139(3):499-511. PMC: 2844890. DOI: 10.1016/j.cell.2009.08.039. View

15.

Miyagi E, Andrew A, Kao S, Strebel K . Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A. 2009; 106(8):2868-73. PMC: 2650357. DOI: 10.1073/pnas.0813223106. View

16.

Mitchell R, Katsura C, Skasko M, Fitzpatrick K, Lau D, Ruiz A . Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009; 5(5):e1000450. PMC: 2679223. DOI: 10.1371/journal.ppat.1000450. View

17.

Zhang F, Wilson S, Landford W, Virgen B, Gregory D, Johnson M . Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 2009; 6(1):54-67. PMC: 2852097. DOI: 10.1016/j.chom.2009.05.008. View

18.

Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y . HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem. 2009; 284(50):35060-72. PMC: 2787367. DOI: 10.1074/jbc.M109.058305. View

19.

Mansouri M, Viswanathan K, Douglas J, Hines J, Gustin J, Moses A . Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol. 2009; 83(19):9672-81. PMC: 2748026. DOI: 10.1128/JVI.00597-09. View

20.

Douglas J, Viswanathan K, McCarroll M, Gustin J, Fruh K, Moses A . Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol. 2009; 83(16):7931-47. PMC: 2715753. DOI: 10.1128/JVI.00242-09. View